LOAD MORE
You're viewed all 10 products
Eltrombopag
References
FAQ's
References
- Moore, Stephen, 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4h-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine), SmithKline Beecham Corp., United States, EP1534390B1, December 23, 2009
- Maddela, Rambabu; Gajula, Ramakrishna; Pilli, Nageswara Rao; Siddiraju, Sridhar; Maddela, Srinubabu; Makula, Ajitha, Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50 μL of human plasma: A pharmacokinetic study, Journal of Pharmaceutical and Biomedical Analysis, Volume: 98, Pages: 68-73, 2014
Frequently Asked Questions
How are the Eltrombopag impurities characterized?
Impurities in Eltrombopag are characterized through various techniques, such as mass spectrometry, infrared spectroscopy, and elemental analysis. These methods help determine the chemical structure and properties of impurities.
Is impurity analysis a continuous process for Eltrombopag?
Impurity analysis is an ongoing process for Eltrombopag, starting from the development stage and continuing throughout its lifecycle. Regular monitoring and analysis ensure the consistency and quality of the drug.
What solvent helps in analyzing Eltrombopag impurities?
DMSO is the solvent used for analyzing many impurities in Eltrombopag.
How should Eltrombopag impurities be stored in terms of temperature?
Eltrombopag impurities are stored at a controlled room temperature, 2-8 °C, or according to the Certificate of Analysis (CoA) specifications.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.